Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 376

1.

Response to Eribulin in a patient with metastatic uterine leiomyosarcoma: a case report.

Aliberti S, Miano S, Tolomeo F, Merlini A, Aglietta M, Grignani G.

Future Oncol. 2020 Jan 9. doi: 10.2217/fon-2019-0597. [Epub ahead of print]

PMID:
31916842
2.

Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).

Atkinson V, Sandhu S, Hospers G, Long GV, Aglietta M, Ferrucci PF, Tulyte S, Cappellini GCA, Soriano V, Ali S, Poprach A, Cesas A, Rodriguez-Abreu D, Lau M, de Jong E, Legenne P, Stein D, King B, van Thienen JV.

Melanoma Res. 2019 Dec 30. doi: 10.1097/CMR.0000000000000654. [Epub ahead of print]

PMID:
31895752
3.

The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer.

Salati M, Filippi R, Vivaldi C, Caputo F, Leone F, Salani F, Cerma K, Aglietta M, Fornaro L, Sperti E, Di Maio M, Ortega C, Fenocchio E, Lombardi P, Cagnazzo C, Depetris I, Gelsomino F, Spallanzani A, Santini D, Silvestris N, Aprile G, Roviello G, Scartozzi M, Cascinu S, Casadei-Gardini A.

Liver Int. 2019 Nov 27. doi: 10.1111/liv.14314. [Epub ahead of print]

PMID:
31773848
4.

Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications.

Giannone G, Attademo L, Scotto G, Genta S, Ghisoni E, Tuninetti V, Aglietta M, Pignata S, Valabrega G.

Cancers (Basel). 2019 Nov 19;11(11). pii: E1820. doi: 10.3390/cancers11111820. Review.

5.

Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018.

Reale ML, De Luca E, Lombardi P, Marandino L, Zichi C, Pignataro D, Ghisoni E, Di Stefano RF, Mariniello A, Trevisi E, Leone G, Muratori L, La Salvia A, Sonetto C, Bironzo P, Aglietta M, Novello S, Scagliotti GV, Perrone F, Di Maio M.

Lung Cancer. 2020 Jan;139:47-54. doi: 10.1016/j.lungcan.2019.10.022. Epub 2019 Oct 31.

PMID:
31734586
6.

Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer?

Fenocchio E, Filippi R, Lombardi P, Quarà V, Milanesio M, Aimar G, Leone F, Aglietta M.

Cancers (Basel). 2019 Oct 12;11(10). pii: E1547. doi: 10.3390/cancers11101547. Review.

7.

Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan.

Fornaro L, Leone F, Vienot A, Casadei-Gardini A, Vivaldi C, Lièvre A, Lombardi P, De Luca E, Vernerey D, Sperti E, Musettini G, Satolli MA, Edeline J, Spadi R, Neuzillet C, Falcone A, Pasquini G, Clerico M, Passardi A, Buscaglia P, Meurisse A, Aglietta M, Brac C, Vasile E, Montagnani F.

Clin Colorectal Cancer. 2019 Dec;18(4):e394-e401. doi: 10.1016/j.clcc.2019.08.004. Epub 2019 Sep 4.

PMID:
31564556
8.

Safe Use of Carfilzomib in a Patient with Multiple Myeloma and Intermittent Type 1 Brugada ECG Pattern: A Case Report.

Ghisoni E, Marandino L, Lombardi P, Bonzano A, Becco P, Aglietta M, Fizzotti M, Gay F, Rota Scalabrini D.

Acta Haematol. 2019 Sep 25:1-5. doi: 10.1159/000502538. [Epub ahead of print]

PMID:
31553985
9.

Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives.

Filippi R, Lombardi P, Quarà V, Fenocchio E, Aimar G, Milanesio M, Leone F, Aglietta M.

Expert Opin Pharmacother. 2019 Dec;20(17):2121-2137. doi: 10.1080/14656566.2019.1667335. Epub 2019 Sep 24. Review.

PMID:
31550186
10.

Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018.

Marandino L, De Luca E, Zichi C, Lombardi P, Reale ML, Pignataro D, Di Stefano RF, Ghisoni E, Mariniello A, Trevisi E, Leone G, Muratori L, La Salvia A, Sonetto C, Buttigliero C, Tucci M, Aglietta M, Novello S, Scagliotti GV, Perrone F, Di Maio M.

Clin Genitourin Cancer. 2019 Oct;17(5):332-347.e2. doi: 10.1016/j.clgc.2019.07.007. Epub 2019 Jul 20. Review.

PMID:
31416754
11.

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses.

Cesne AL, Bauer S, Demetri GD, Han G, Dezzani L, Ahmad Q, Blay JY, Judson I, Schöffski P, Aglietta M, Hohenberger P, Gelderblom H.

BMC Cancer. 2019 Aug 13;19(1):794. doi: 10.1186/s12885-019-5988-3.

12.

CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy.

Rotolo R, Leuci V, Donini C, Cykowska A, Gammaitoni L, Medico G, Valabrega G, Aglietta M, Sangiolo D.

Int J Mol Sci. 2019 Jun 11;20(11). pii: E2839. doi: 10.3390/ijms20112839. Review.

13.

Preventing Venous Thromboembolism in Patients with Cancer.

D'Ambrosio L, Aglietta M, Grignani G.

N Engl J Med. 2019 May 30;380(22):2180-2181. doi: 10.1056/NEJMc1904003. No abstract available.

14.

Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program.

Martin-Algarra S, Hinshelwood R, Mesnage S, Cebon J, Ferrucci PF, Aglietta M, Neyns B, Chiarion-Sileni V, Lindsay CR, Del Vecchio M, Linardou H, Merelli B, Tonini G, Atkinson V, Freivogel K, Stein D, Dalland L, Lau M, Legenne P, Queirolo P, Millward M.

Melanoma Res. 2019 Oct;29(5):527-532. doi: 10.1097/CMR.0000000000000608.

PMID:
31095039
15.

Veliparib: a new therapeutic option in ovarian cancer?

Ghisoni E, Giannone G, Tuninetti V, Genta S, Scotto G, Aglietta M, Sangiolo D, Mittica G, Valabrega G.

Future Oncol. 2019 Jun;15(17):1975-1987. doi: 10.2217/fon-2018-0883. Epub 2019 May 10. Review.

PMID:
31074636
16.

NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives.

Lo Nigro C, Macagno M, Sangiolo D, Bertolaccini L, Aglietta M, Merlano MC.

Ann Transl Med. 2019 Mar;7(5):105. doi: 10.21037/atm.2019.01.42. Review.

17.

Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine.

Varamo C, Peraldo-Neia C, Ostano P, Basiricò M, Raggi C, Bernabei P, Venesio T, Berrino E, Aglietta M, Leone F, Cavalloni G.

Cancers (Basel). 2019 Apr 11;11(4). pii: E519. doi: 10.3390/cancers11040519.

18.

Assessment of a High Sensitivity Method for Identification of IDH1 R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients.

Peraldo-Neia C, Scatolini M, Grosso E, Lombardi P, Filippi R, Raggi C, Marchiò C, Cavalloni G, Aglietta M, Leone F.

Cancers (Basel). 2019 Mar 30;11(4). pii: E454. doi: 10.3390/cancers11040454.

19.

Improvement of Metastatic Colorectal Cancer Patient Survival: Single Institution Experience.

Fenocchio E, Colombi F, Calella MG, Filippi R, Depetris I, Chilà G, Lombardi P, Marino D, Cagnazzo C, Ferraris R, Vaira M, Aglietta M, Leone F.

Cancers (Basel). 2019 Mar 15;11(3). pii: E369. doi: 10.3390/cancers11030369.

20.

TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers.

Ghisoni E, Maggiorotto F, Borella F, Mittica G, Genta S, Giannone G, Katsaros D, Sciarrillo A, Ferrero A, Sarotto I, Erriquez J, Di Renzo MF, Aglietta M, Valabrega G.

J Ovarian Res. 2019 Feb 13;12(1):17. doi: 10.1186/s13048-019-0492-6.

21.

Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours.

Martin V, Chiriaco C, Modica C, Acquadro A, Cortese M, Galimi F, Perera T, Gammaitoni L, Aglietta M, Comoglio PM, Vigna E, Sangiolo D.

Br J Cancer. 2019 Mar;120(5):527-536. doi: 10.1038/s41416-018-0315-3. Epub 2019 Feb 6.

22.

"Shades of Gray" in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated indications for surgery in pancreatic cancer.

Lombardi P, Silvestri S, Marino D, Santarelli M, Campra D, De Paolis P, Aglietta M, Leone F; Rete Oncologica Piemonte e Valle d’Aosta.

Crit Rev Oncol Hematol. 2019 Jan;133:17-24. doi: 10.1016/j.critrevonc.2018.10.009. Epub 2018 Nov 2. Review.

PMID:
30661653
23.

Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis.

Vernieri C, Galli F, Ferrari L, Marchetti P, Lonardi S, Maiello E, Iaffaioli RV, Zampino MG, Zaniboni A, De Placido S, Banzi M, Damiani A, Ferrari D, Rosati G, Labianca RF, Bidoli P, Frassineti GL, Nicolini M, Pavesi L, Tronconi MC, Buonadonna A, Ferrario S, Re GL, Adamo V, Tamburini E, Clerico M, Giordani P, Leonardi F, Barni S, Ciarlo A, Cavanna L, Gori S, Cinieri S, Faedi M, Aglietta M, Antista M, Dotti KF, Galli F, Di Bartolomeo M; TOSCA (Three or Six Colon Adjuvant) Investigators.

Oncologist. 2019 Mar;24(3):385-393. doi: 10.1634/theoncologist.2018-0442. Epub 2019 Jan 3.

24.

Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.

Mesiano G, Grignani G, Fiorino E, Leuci V, Rotolo R, D'Ambrosio L, Salfi C, Gammaitoni L, Giraudo L, Pisacane A, Butera S, Pignochino Y, Basiricó M, Capozzi F, Sapino A, Aglietta M, Sangiolo D.

Oncoimmunology. 2018 Aug 6;7(11):e1465161. doi: 10.1080/2162402X.2018.1465161. eCollection 2018.

25.

Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016.

Marandino L, La Salvia A, Sonetto C, De Luca E, Pignataro D, Zichi C, Di Stefano RF, Ghisoni E, Lombardi P, Mariniello A, Reale ML, Trevisi E, Leone G, Muratori L, Marcato M, Bironzo P, Novello S, Aglietta M, Scagliotti GV, Perrone F, Di Maio M.

Ann Oncol. 2018 Dec 1;29(12):2288-2295. doi: 10.1093/annonc/mdy449.

26.

Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.

Grignani G, D'Ambrosio L, Pignochino Y, Palmerini E, Zucchetti M, Boccone P, Aliberti S, Stacchiotti S, Bertulli R, Piana R, Miano S, Tolomeo F, Chiabotto G, Sangiolo D, Pisacane A, Dei Tos AP, Novara L, Bartolini A, Marchesi E, D'Incalci M, Bardelli A, Picci P, Ferrari S, Aglietta M.

Lancet Oncol. 2018 Oct;19(10):1360-1371. doi: 10.1016/S1470-2045(18)30438-8. Epub 2018 Sep 11.

PMID:
30217671
27.

Rationale for the use of metronomic chemotherapy in gastrointestinal cancer.

Filippi R, Lombardi P, Depetris I, Fenocchio E, Quarà V, Chilà G, Aglietta M, Leone F.

Expert Opin Pharmacother. 2018 Sep;19(13):1451-1463. doi: 10.1080/14656566.2018.1512585. Epub 2018 Aug 30. Review.

PMID:
30161003
28.

Bone metastases in biliary cancers: A multicenter retrospective survey.

Santini D, Brandi G, Aprile G, Russano M, Cereda S, Leone F, Lonardi S, Fornaro L, Scartozzi M, Silvestris N, Barni S, Pantano F, Vincenzi B, Palloni A, Frega G, Casagrande M, Ferrari L, Dadduzio V, Intini R, Filippi R, Vasile E, Vivaldi C, Faloppi L, Brunetti O, Reni M, Aglietta M, Tonini G.

J Bone Oncol. 2018 Apr 7;12:33-37. doi: 10.1016/j.jbo.2017.11.006. eCollection 2018 Sep.

29.

Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study.

Galizia D, Milani A, Geuna E, Martinello R, Cagnazzo C, Foresto M, Longo V, Berchialla P, Solinas G, Calori A, Grasso B, Volpone C, Bertola G, Parola G, Tealdi G, Giuliano PL, Ballari AM, Aglietta M, Montemurro F.

Cancer Med. 2018 Sep;7(9):4339-4344. doi: 10.1002/cam4.1687. Epub 2018 Jul 20.

30.

Survivin-peptide vaccination elicits immune response after allogeneic nonmyeloablative transplantation: a safe strategy to enhance the graft versus tumor effect.

Circosta P, Vitaggio K, Elia AR, Todorovic M, Sangiolo D, Carnevale-Schianca F, Vallario A, Geuna M, Aglietta M, Cignetti A.

Immunotherapy. 2018 Jul;10(9):753-767. doi: 10.2217/imt-2017-0139.

PMID:
30008257
31.

Next generation immune-checkpoints for cancer therapy.

Donini C, D'Ambrosio L, Grignani G, Aglietta M, Sangiolo D.

J Thorac Dis. 2018 May;10(Suppl 13):S1581-S1601. doi: 10.21037/jtd.2018.02.79. Review.

32.

Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma.

Peraldo-Neia C, Ostano P, Cavalloni G, Pignochino Y, Sangiolo D, De Cecco L, Marchesi E, Ribero D, Scarpa A, De Rose AM, Giuliani A, Calise F, Raggi C, Invernizzi P, Aglietta M, Chiorino G, Leone F.

BMC Genomics. 2018 Jun 5;19(1):440. doi: 10.1186/s12864-018-4829-0.

33.

A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.

Ghisoni E, Katsaros D, Maggiorotto F, Aglietta M, Vaira M, De Simone M, Mittica G, Giannone G, Robella M, Genta S, Lucchino F, Marocco F, Borella F, Valabrega G, Ponzone R.

J Ovarian Res. 2018 May 30;11(1):42. doi: 10.1186/s13048-018-0415-y.

34.

CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.

Leuci V, Casucci GM, Grignani G, Rotolo R, Rossotti U, Vigna E, Gammaitoni L, Mesiano G, Fiorino E, Donini C, Pisacane A, Ambrosio LD, Pignochino Y, Aglietta M, Bondanza A, Sangiolo D.

Oncoimmunology. 2018 Feb 15;7(5):e1423167. doi: 10.1080/2162402X.2017.1423167. eCollection 2018.

35.

BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 Antibody.

Sanlorenzo M, Vujic I, Floris A, Novelli M, Gammaitoni L, Giraudo L, Macagno M, Leuci V, Rotolo R, Donini C, Basiricò M, Quaglino P, Fierro MT, Giordano S, Sibilia M, Carnevale-Schianca F, Aglietta M, Sangiolo D.

Clin Cancer Res. 2018 Jul 15;24(14):3377-3385. doi: 10.1158/1078-0432.CCR-17-1914. Epub 2018 Apr 12.

36.

Fluoropyrimidine-induced cardiotoxicity.

Depetris I, Marino D, Bonzano A, Cagnazzo C, Filippi R, Aglietta M, Leone F.

Crit Rev Oncol Hematol. 2018 Apr;124:1-10. doi: 10.1016/j.critrevonc.2018.02.002. Epub 2018 Feb 7. Review.

PMID:
29548480
37.

PARP Inhibitors in Ovarian Cancer.

Mittica G, Ghisoni E, Giannone G, Genta S, Aglietta M, Sapino A, Valabrega G.

Recent Pat Anticancer Drug Discov. 2018;13(4):392-410. doi: 10.2174/1574892813666180305165256. Review.

PMID:
29512470
38.

Emerging molecular target antagonists for the treatment of biliary tract cancer.

Lombardi P, Marino D, Fenocchio E, Chilà G, Aglietta M, Leone F.

Expert Opin Emerg Drugs. 2018 Mar;23(1):63-75. doi: 10.1080/14728214.2018.1444749. Epub 2018 Feb 28. Review.

39.

Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice.

Nannini M, Nigro MC, Vincenzi B, Fumagalli E, Grignani G, D'Ambrosio L, Badalamenti G, Incorvaia L, Bracci R, Gasperoni S, Saponara M, Gatto L, Indio V, Astolfi A, Di Scioscio V, Casali PG, Tonini G, Aglietta M, Russo A, Biasco G, Pantaleo MA.

Ther Adv Med Oncol. 2017 Dec;9(12):731-739. doi: 10.1177/1758834017742627. Epub 2017 Dec 19.

40.

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, André T.

J Clin Oncol. 2018 Mar 10;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20.

41.

Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR.

Peraldo-Neia C, Cavalloni G, Fenocchio E, Cagnazzo C, Gammaitoni L, Cereda S, Nasti G, Satolli MA, Aprile G, Reni M, Avallone A, Spadi R, Venesio T, Martin V, Doglioni C, Frattini M, Aglietta M, Leone F.

PLoS One. 2018 Jan 19;13(1):e0191593. doi: 10.1371/journal.pone.0191593. eCollection 2018.

42.

Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: a prospective evaluation.

Prati V, Ruatta F, Aversa C, Gernone A, Galizia D, Bonzano A, Torino S, Nuzzolese I, Marandino L, Aglietta M, Ortega C.

Future Oncol. 2018 Feb;14(5):443-448. doi: 10.2217/fon-2017-0385. Epub 2018 Jan 10.

PMID:
29318908
43.

BRAF-inhibitors can exert control of disease in BRAF T599I mutated melanoma: a case report.

Gallo S, Coha V, Caravelli D, Becco P, Venesio T, Zaccagna A, Giacone E, Marenco F, Pisacane A, Racca M, Gammaitoni L, Aglietta M, Carnevale-Schianca F.

Melanoma Res. 2018 Apr;28(2):143-146. doi: 10.1097/CMR.0000000000000417.

PMID:
29232305
44.

Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity.

Mittica G, Ghisoni E, Giannone G, Aglietta M, Genta S, Valabrega G.

Oncotarget. 2017 Aug 8;8(52):90532-90544. doi: 10.18632/oncotarget.20042. eCollection 2017 Oct 27. Review.

45.

Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer.

Gobbini E, Pilotto S, Pasello G, Polo V, Di Maio M, Arizio F, Galetta D, Petrillo P, Chiari R, Matocci R, Di Costanzo A, Di Stefano TS, Aglietta M, Cagnazzo C, Sperduti I, Bria E, Novello S.

Clin Lung Cancer. 2018 Mar;19(2):191-198. doi: 10.1016/j.cllc.2017.10.012. Epub 2017 Oct 28.

PMID:
29153968
46.

Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas.

Vincenzi B, Badalamenti G, Napolitano A, Spalato Ceruso M, Pantano F, Grignani G, Russo A, Santini D, Aglietta M, Tonini G.

Crit Rev Oncol Hematol. 2017 Oct;118:1-6. doi: 10.1016/j.critrevonc.2017.06.006. Epub 2017 Jul 15. Review.

PMID:
28917265
47.

Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells.

Mesiano G, Zini R, Montagner G, Bianchi N, Manfredini R, Chillemi A, Aglietta M, Grignani G, Lampronti I, Fiorino E, Malavasi F, Sangiolo D, Gambari R, Ferrari D.

Mol Med. 2017 Oct;23:235-246. doi: 10.2119/molmed.2017.00084. Epub 2017 Aug 9.

48.

Treating breast cancer with cell-based approaches: an overview.

Gallo S, Sangiolo D, Carnevale Schianca F, Aglietta M, Montemurro F.

Expert Opin Biol Ther. 2017 Oct;17(10):1255-1264. doi: 10.1080/14712598.2017.1356816. Epub 2017 Jul 20. Review.

PMID:
28728493
49.

Front-line window therapy with cisplatin in patients with primary disseminated Ewing sarcoma: A study by the Associazione Italiana di Ematologia ed Oncologia Pediatrica and Italian Sarcoma Group.

Luksch R, Grignani G, D'Angelo P, Prete A, Puma N, Podda M, Casanova M, Ferrari A, Morosi C, Fagioli F, Aglietta M, Ferrari S, Picci P, Massimino M.

Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26650. Epub 2017 Jun 14.

PMID:
28612488
50.

Androgen receptor status predicts development of brain metastases in ovarian cancers.

Mittica G, Senetta R, Scotto G, Aglietta M, Maggiorotto F, Ghisoni E, Genta S, Boldorini R, Manini C, Morra I, Buosi R, Sapino A, Cassoni P, Valabrega G.

Oncotarget. 2017 Jun 20;8(25):41143-41153. doi: 10.18632/oncotarget.17068.

Supplemental Content

Loading ...
Support Center